Differential requirements for CD4+ T cells in the efficacy of the anti-PD-1+LAG-3 and anti-PD-1+CTLA-4 combinations in melanoma flank and brain metastasis models.

11 The observation that these two different, Food and Drug Administration (FDA)-approved ICI combinations have different mechanisms of action is highly significant.

also in 132,142 other papers

An analysis of myeloid cells did not reveal a clear trend over the 14 day time period ( online supplemental figure 2 : Gating strategy for myeloid-derived suppressor cells (MDSCs) shown in online supplemental figure 3 ).

also in 19,460 other papers